WEREWOLF THERAP. DL-,0001

Werewolf Therapeutics will merge with Ambros Therapeutics in an all-stock transaction; the announcement lifted the share price intraday by about 114%. A heavily oversubscribed private placement of $150 million, led by RA Capital Management and Janus Henderson, values Ambros at $500 million pre-money and Werewolf at $47.5 million. The combined company is expected to trade on Nasdaq as Ambros Therapeutics (AMBX); closing is anticipated in Q1 2027. The deal focuses on neridronate (Phase‑3 study CRPS‑RISE), with topline data due in 2028, and the funding is intended to support operations and regulatory plans into H1 2029. » More on de.investing.com

Werewolf Therapeutics announced a 64% workforce reduction; the stock fell about 5.1% in after-hours trading on Friday. The board approved the measure on Feb. 9; the layoffs are to be completed by Feb. 13. The company expects a one-time charge of about $4.1 million in Q1 2026 and plans to reduce operating costs. CFO Timothy W. Trost and CMO Dr. Randi Isaacs will resign effective Feb. 13; Michael Urban will assume interim finance duties. Werewolf is exploring financing options and strategic partnerships for the INDUKINE programs WTX-124 and WTX-330. » More on de.investing.com

After the death of Dr. Alon Lazarus, Werewolf Therapeutics now has only two members on its audit committee and therefore no longer meets NASDAQ’s minimum requirement of three independent members. The company has informed NASDAQ and plans to appoint another independent member promptly; the deadline to regain compliance runs until the next annual meeting or September 30, 2026. In addition, Citizens JMP lowered its price target for Werewolf Therapeutics from $4.00 to $3.00 but maintained a “Market Outperform” rating. » More on de.investing.com